MSPs get to benefit from every important IT trend that comes along, whether that's cybersecurity or data and AI,' said FFL's ...

MDCX ’s lead asset is Skinkject, a patented innovative product intended to address the most commonly occurring cancer, which is skin cancer, or Basal Cell Carcinoma (BCC). Skinject is a thumb-sized ...

Abacus Group and Medicus IT, two leading providers of IT managed services with deep subject matter expertise in the highly ...

FFL Partners ("FFL"), a private equity firm focused on growth investments in tech-enabled business services and healthcare companies, today announced the completion of the merger of FFL portfolio ...

Medicus Pharma offers high-risk, high-reward potential, with its novel SkinJect patch for basal cell carcinoma and Antev ...

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in. The post Is it too late to ...

Review quarterly and annual revenue, net income, and cash flow for Pro Medicus Ltd (PME:XASX) stock through the last fiscal year.

Whenever the healthcare imaging software group signs a new customer contract, fund managers hide under their desks. This latest one really hurts.

Medicus to acquire Antev and expand into urology with Teverelix while reporting positive data in its Phase 2 skin cancer trial for D-MNA.

The Pro Medicus Ltd (ASX: PME) share price is racing higher today. Here’s why investors are piling into the ASX 200 ...

Pro Medicus Ltd (ASX: PME) shares have been on fire over the past 12 months. Are they finally reaching a top? Let's find ...

Subject to the closing conditions noted in the Definitive Agreement, Medicus will acquire all issued and outstanding Antev Shares, on a fully diluted basis, in exchange for 2,666,600 (or ...